Niraparib has relatively obvious off-target effects and has a strong effect on targets such as serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET), which may be related to adverse reactions such as high blood pressure (Montastruc et al., 2020; Staropoli et al., 2018). Here, SLC6A2 is linked to hypertensive disorder.